![](https://endpts.com/wp-content/uploads/2020/06/Doug-Ingram-Sarepta-tile-scaled.jpg)
Doug Ingram (file photo)
Why not? Sarepta’s third Duchenne MD drug sails to accelerated approval
Sarepta may be running into some trouble with its next-gen gene therapy approach to Duchenne muscular dystrophy. But when it comes to antisense oligonucleotides, the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.